Abstract:Resumo Introdução e objetivos : O presente estudo avalia o efeito do ácido quelidónico na toxicidade cardíaca induzida pela doxorrubicina. O ácido quelidónico é um composto heterocíclico natural do esqueleto pirano encontrado nos rizomas da planta perene, celidónia (Chelidonium majus). Métodos : Ratos Wistar receberam injeção intraperitoneal de doxorrubicina (1,25 mg/kg, dose cumulativa de 20 mg/kg) quatro vezes por semana durante quatro semanas para induzir cardiotoxicidade. O tratamento com ácido quelidónico (10, 20 e 40 mg/kg por via oral durante quatro semanas) foi iniciado juntamente com a doxorrubicina. Resultados : O tratamento com ácido quelidónico reduziu o dano miocárdico e melhorou a disfunção cardíaca em ratos tratados com doxorrubicina. O tratamento com ácido quelidónico melhorou a pressão arterial, bem como restaurou a altura ST e normalizou o intervalo QTc em comparação com os únicos ratos tratados com doxorrubicina. A administração de ácido quelidónico por quatro semanas reduziu a pressão diastólica final do ventrículo esquerdo. Além disso, o tratamento com ácido quelidónico diminuiu o nível de marcadores cardíacos como creatina quinase-banda miocárdica (CK-MB), lactato desidrogenase (LDH), aspartato aminotransferase (AST) e troponina T cardíaca. A coloração com tricrómico, hematoxilina e eosina de Masson do tecido cardíaco revelou que o ácido quelidónico atenuou os efeitos deletérios da doxorrubicina e preveniu maiores danos e fibrose em ratos. Conclusão : Os achados do presente estudo confirmam que o tratamento com ácido quelidónico pode proteger o miocárdio contra a cardiotoxicidade induzida pela doxorrubicina. Introduction and objectives: The current study evaluates the effect of chelidonic acid on doxorubicin-induced cardiac toxicity. Chelidonic acid (CA) is a natural pyran-skeleton heterocyclic compound found in rhizomes of the perennial plant, celandine ( Chelidonium majus ). Methods: Wistar rats were given an intraperitoneal injection of doxorubicin (1.25 mg/kg, cumulative dose of 20 mg/kg) four times per week for a duration of four weeks to induce cardiotoxicity. CA treatment (10, 20, and 40 mg/kg orally for four weeks) was started together with doxorubicin. Results: CA treatment reduced myocardial damage and improved cardiac dysfunction in doxorubicin-treated rats. It improved blood pressure, restored ST wave height and normalized the QTc interval compared to the rats treated only with doxorubicin. Administration of CA for four weeks reduced left ventricular end-diastolic pressure. Moreover, CA treatment decreased the level of cardiac markers such as creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and cardiac troponin-T. Masson's trichrome, hematoxylin, and eosin staining of heart tissue revealed that CA attenuated the deleterious effects of doxorubicin and prevented further damage and fibrosis in rats. Conclusion: The study findings confirm that CA treatment can protect the myocardium against doxorubicin-induced cardiotoxicity.

Cardioprotective effect of chelidonic acid against doxorubicin-induced cardiac toxicity in rats

Mitigating Doxorubicin-Induced Cardiotoxicity through Quercetin Intervention: An Experimental Study in Rats

Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction

Acetylcholine receptor agonists provide cardioprotection in doxorubicin-induced cardiotoxicity via modulating muscarinic M2 and α7 nicotinic receptor expression

Primary Protection of Diosmin Against Doxorubicin Cardiotoxicity via Inhibiting Oxido-Inflammatory Stress and Apoptosis in Rats

Citronellal alleviates doxorubicin‐induced cardiotoxicity by suppressing oxidative stress and apoptosis via Na + /H + exchanger‐1 inhibition

Cardioprotective Effects of Leucine Supplementation against Doxorubicin-Induced Cardiotoxicit

The Protective Effects of Carvacrol Against Doxorubicin-Induced Cardiotoxicity In Vitro and In Vivo

Cinnamaldehyde alleviates doxorubicin-induced cardiotoxicity by decreasing oxidative stress and ferroptosis in cardiomyocytes

Liposomal Resveratrol and/or Carvedilol Attenuate Doxorubicin-Induced Cardiotoxicity by Modulating Inflammation, Oxidative Stress and S100A1 in Rats

Electrocardiographic, biochemical, and scintigraphic evidence for the cardioprotective effect of paricalcitol and vitamin D3 on doxorubicin-induced acute cardiotoxicity in rats

Doxycycline Attenuates Doxorubicin-Induced Cardiotoxicity by Improving Myocardial Energy Metabolism in Rats

Chemical Endoplasmic Reticulum Chaperone Alleviates Doxorubicin-Induced Cardiac Dysfunction

Cardioprotective effect of vanillic acid against doxorubicin-induced cardiotoxicity in rat

Asiatic Acid Protects against Doxorubicin-Induced Cardiotoxicity in Mice

AICAR confers prophylactic cardioprotection in doxorubicin-induced heart failure in rats

Scutellarin Attenuates Doxorubicin‐Induced Cardiotoxicity by Inhibiting Myocardial Fibrosis, Apoptosis and Autophagy in Rats

Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling.

A Combination of Cardamonin and Doxorubicin Selectively Affect Cell Viability of Melanoma Cells: An In Vitro Study

P3115Effect of calcitriol attenuates doxorubicin-induced cardiac dysfunction in mice model: focus on endothelial-to-mesenchymal transition

Quercetin Improves Postischemic Recovery of Heart Function in Doxorubicin-Treated Rats and Prevents Doxorubicin-Induced Matrix Metalloproteinase-2 Activation and Apoptosis Induction